Looks like Dr Bec succeeded here as a follow up from August 2024
Sydney, Australia, 09 August 2024: Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce a collaboration with Cell Therapies Pty Ltd to explore the potential to manufacture Chimeric’s CAR T assets in Australia. Cell Therapies Pty Ltd (“CTPL” or “Cell Therapies”) is an Australian based commercial contract development and manufacturing company, specialising in cell therapy, gene therapy, regenerative medicine, and cellular immunotherapy products. CTPL’s facilities are co-located with the Peter MacCallum Cancer Centre in Melbourne’s Parkville Precinct and are Australia’s only biomedical manufacturing facility where CAR T-cells and other “living” cancer therapies can be made at a commercial scale.
And those who follow IMU will have read about the FDA now a bit more pro towards CAR-Ts.
At least the clinical side of CHM is having a bit of sunshine. Now the MAN has to follow by NOT creating another down pour.
CHM Price at posting:
0.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)